Company news

Bolt Biotherapeutics, Inc. news in 2021

Bolt Biotherapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors

December 15, 2021

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

December 5, 2021

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

December 1, 2021

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

November 8, 2021

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors

September 7, 2021

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

August 25, 2021

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

August 11, 2021

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

June 3, 2021

Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights

May 12, 2021

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

April 9, 2021

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

March 30, 2021

Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 8, 2021

Decks in 2021